secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-10-06T12:30:20+00:00
Accession:  0001493152-26-045867
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

bioAffinity reports CyPath Lung sales up over 100% through Q3 2026
------------------------------------------------------------------

- CyPath Lung sales rose more than 100% through Q3 2026 versus 2025, with 1,620 tests delivered compared to 775 in Q3 2025.
- Ordering physicians increased 89% in Q3 2026 versus Q3 2025; prior prescribers' sales volume rose 48% year-over-year.
- CEO Maria Zannes cited a new distribution agreement with Veteran-Owned AvMEDICAL to broaden reach in government healthcare, including the Department of Veterans Affairs.
- CyPath Lung reported 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in high-risk patients with nodules under 20 mm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226045867/0001493152-26-045867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226045867/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-045867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer